Cassava Dives Again After Investors Spooked By Alzheimer’s Drug Fraud Claims
Lab Test Company Did Not Conduct Data Analysis
Executive Summary
Cassava’s claims that its drug reversed cognitive decline in Alzheimer’s patients are seen as "too good to be true" by skeptics. A statement by former lab services partner Quanterix has further undermined investor confidence.